JAMA dermatology
-
Randomized Controlled Trial Multicenter Study Comparative Study
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Risankizumab selectively inhibits interleukin 23, a cytokine that contributes to psoriatic inflammation. ⋯ Risankizumab showed superior efficacy compared with placebo through 16 weeks and treatment withdrawal through 2 years. Risankizumab was well tolerated, with no unexpected safety findings during the 2-year trial.